Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 4
1(33.3%)
3Total
N/A(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05487885Phase 4Completed

Anhedonia, Development, and Emotions: Phenotyping and Therapeutics

Role: lead

NCT05436379Not ApplicableCompleted

Treatment, Emotion, and Neuromodulation of Depression (TREND) Study

Role: lead

NCT03737032Not ApplicableCompleted

Theta Burst Stimulation in Young Adults With Depression

Role: lead

All 3 trials loaded